All In Biotech

NDA 020503 · Kindeva

Proventil-Hfa

Albuterol Sulfate · Inhalation

Last checked: Nov 19, 2026Latest source record: Sep 22, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Aug 15, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

90,414

36,444 serious, 4,049 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2026.

INDICATIONS AND USAGE Albuterol Sulfate Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Mechanism: Mechanism of Action In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50% of cardiac beta-adrenergic receptors. The precise function of these receptors has not been established. (See WARNINGS, Cardiovascular Effects section.) Activation...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 2, 1999 Supplement 11 · Efficacy ReviewLetter
  • Sep 23, 1998 Supplement 4 · Efficacy LabelReviewLetter
  • Aug 15, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • PROVENTIL-HFA · ALBUTEROL SULFATE EQ 0.09MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea13,491
  • wrong technique in product usage process10,981
  • no adverse event8,673
  • device delivery system issue8,098
  • drug dose omission by device7,914
  • asthma7,044
  • cough6,601
  • drug ineffective5,519
  • fatigue5,275
  • product dose omission issue5,123
  • headache4,994
  • off label use4,917

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004280
200592
200673
200799
2008345
2009162
2010191
2011353
2012496
2013539
2014665
20151,214
20162,108
20171,648
20181,882
20192,802
20206,163
20218,141
20229,724
202312,688
202414,923
202514,933
202610,893

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Proventil HFA (Albuterol Sulfate)

2024 spending

$7K

Beneficiaries

73

101 claims

Per beneficiary

$98

$9.98 per unit

View as table
YearSpending
2020$0
2021$271,921
2022$990,360
2023$333,109
2024$7,133

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 986 on PubMed

Sponsor: Kindeva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.